Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 14 of 25, showing 5 Applications out of 121 total, starting on record 66, ending on 70

# Protocol No Study Title Investigator(s) & Site(s)

66.

ECCT/19/11/06   Optimize LNG EC
    An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375   
Principal Investigator(s)
1. Lucy Chepkurui Koech
Site(s) in Kenya
KEMRI/WRP Kericho
 
View

67.

ECCT/20/04/02   PROSYNK Study
    A 4-arm, open-label, individually randomized, controlled, phase-2, study of a probiotic and two synbiotics in young children in western Kenya.   
Principal Investigator(s)
1. Stephen Allen
Site(s) in Kenya
1. Homa Bay County Referral Hospital (Homa Bay county)
2. Siaya County Referral Hospital (Siaya county)
3. Migori County Referral Hospital (Migori county)
4. Rongo Sub-County Hospital (Migori county)
5. Rachuonyo Sub County Hospital (Homa Bay county)
6. Kendu Bay Sub-County Hospital (Homa Bay county)
7. Ahero County Hospital (Kisumu county)
8. Rabuor Sub-County Hospital (Kisumu county)
9. Akala Sub-County Hospital (Siaya county)
10. Bondo Sub-County Hospital (Siaya county)
 
View

68.

ECCT/19/12/01   BOHEMIA PK400
    Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for BOHEMIA cluster randomized controlled trial.   
Principal Investigator(s)
1. Marta Ferreira Maia
Site(s) in Kenya
Kilifi
 
View

69.

ECCT/19/10/02   AMC-100
    A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals with Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA)   
Principal Investigator(s)
1. NAFTALI WISINDI BUSAKHALA
Site(s) in Kenya
MOI UNIVERSITY CLINICAL RESEARCH CENTER
 
View

70.

ECCT/19/11/01   A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults.
    Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults.   
Principal Investigator(s)
1. Melissa Kapulu
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
View